Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors
Brief Summary: To investigate the safety and efficacy of nivolumab as a single agent or in combination with ipilimumab in 6 tumor types - triple-negative breast cancer (TNBC), gastric cancer (GC), pancreatic adenocarcinoma (PC), small cell lung cancer (SCLC), bladder cancer (BC), and ovarian cancer (OC). A combination of nivolumab with ipilimumab and cobimetinib is also investigated in PC.


Options:
A: Arm Label: Nivolumab; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab | Intervention Type: DRUG; Name: Nivolumab; Assigned to Arm(s): Nivolumab
B: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: paclitaxel, Drug: vinflunine, Drug: docetaxel | Arm Label: Pembrolizumab; Type: EXPERIMENTAL; Interventions: Biological: pembrolizumab | Intervention Type: BIOLOGICAL; Name: pembrolizumab; Assigned to Arm(s): Pembrolizumab | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): Control | Intervention Type: DRUG; Name: vinflunine; Assigned to Arm(s): Control | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): Control
C: Arm Label: Arm N - Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Arm N-I, Level 1: Nivolumab+Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm N-I, Level 2: Nivolumab+Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm N-I, Level 2b: Nivolumab+Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm N-I, Level 2c: Nivolumab+Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm N-I, Level 2d: Nivolumab+Ipilimumab+Cobimetinib; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab, Drug: Cobimetinib | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm N - Nivolumab, Arm N-I, Level 1: Nivolumab+Ipilimumab, Arm N-I, Level 2: Nivolumab+Ipilimumab, Arm N-I, Level 2b: Nivolumab+Ipilimumab, Arm N-I, Level 2c: Nivolumab+Ipilimumab, Arm N-I, Level 2d: Nivolumab+Ipilimumab+Cobimetinib | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Arm N-I, Level 1: Nivolumab+Ipilimumab, Arm N-I, Level 2: Nivolumab+Ipilimumab, Arm N-I, Level 2b: Nivolumab+Ipilimumab, Arm N-I, Level 2c: Nivolumab+Ipilimumab, Arm N-I, Level 2d: Nivolumab+Ipilimumab+Cobimetinib | Intervention Type: DRUG; Name: Cobimetinib; Assigned to Arm(s): Arm N-I, Level 2d: Nivolumab+Ipilimumab+Cobimetinib
D: Arm Label: Arm A: Atezolizumab; Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody | Arm Label: Arm B: Chemotherapy (Vinflunine, Paclitaxel, or Docetaxel); Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel, Drug: Paclitaxel, Drug: Vinflunine | Intervention Type: DRUG; Name: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody; Assigned to Arm(s): Arm A: Atezolizumab | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Arm B: Chemotherapy (Vinflunine, Paclitaxel, or Docetaxel) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm B: Chemotherapy (Vinflunine, Paclitaxel, or Docetaxel) | Intervention Type: DRUG; Name: Vinflunine; Assigned to Arm(s): Arm B: Chemotherapy (Vinflunine, Paclitaxel, or Docetaxel)

Answer: C